Latest MBRX reports update at 2024-03-22: 2023 ∙ 2022

Moleculin Biotech MBRX

$ 4.77 2.8%

Moleculin Biotech Balance Sheet 2011-2024 | MBRX

Annual Balance Sheet Moleculin Biotech

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-23.1 M	-42.8 M	-70.8 M	-14.9 M	-10.4 M	-7.13 M	-7.71 M	-4.71 M	422 K	-	-	-	-
Long Term Debt	474 K	335 K	63 K	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	-	-	-	-	103 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	8.35 M	6.09 M	1.44 M	150 K	87.5 K	-	-	-	-	-
Total Current Liabilities	6.82 M	4.82 M	3.62 M	2.92 M	3.57 M	3.88 M	2.22 M	1.35 M	-	-	-	-	-
Total Liabilities	12.1 M	5.23 M	5.1 M	11.3 M	9.66 M	5.31 M	2.36 M	1.43 M	773 K	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-132 M	-102 M	-72.8 M	-56.9 M	-39.6 M	-26.4 M	-14.5 M	-4.67 M	-748 K	-	-	-	-
Total Assets	38.2 M	57.4 M	84.1 M	29 M	25.2 M	19.6 M	19.5 M	16.4 M	28.1 K	-	-	-	-
Cash and Cash Equivalents	23.6 M	43.1 M	70.9 M	15.2 M	10.7 M	7.13 M	7.71 M	5.01 M	28.1 K	-	-	-	-
Book Value	26.1 M	52.2 M	79 M	17.8 M	15.6 M	14.3 M	17.1 M	15 M	-745 K	-	-	-	-
Total Shareholders Equity	26.1 M	52.2 M	79 M	17.8 M	15.6 M	14.3 M	17.1 M	15 M	-745 K	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Moleculin Biotech

	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	496 K	291 K	308 K	335 K	365 K	388 K	50 K	63 K	75 K	94 K	127 K	159 K	159 K	159 K	159 K	276 K	276 K	276 K	276 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	4.38 M	6.85 M	5.38 M	5.23 M	6.96 M	6.9 M	6.14 M	5.1 M	7.44 M	8.83 M	11.3 M	11.3 M	11.3 M	11.3 M	11.3 M	9.66 M	9.66 M	9.66 M	9.66 M	5.31 M	5.31 M	5.31 M	5.31 M	2.36 M	2.36 M	2.36 M	2.36 M	1.43 M	1.43 M	1.43 M	1.43 M	773 K	773 K	773 K	773 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-121 M	-116 M	-110 M	-102 M	-95.1 M	-86.5 M	-79.7 M	-72.8 M	-70 M	-65.6 M	-61.4 M	-56.9 M	-56.9 M	-56.9 M	-56.9 M	-39.6 M	-39.6 M	-39.6 M	-39.6 M	-26.4 M	-26.4 M	-26.4 M	-26.4 M	-14.5 M	-14.5 M	-14.5 M	-14.5 M	-4.68 M	-4.68 M	-4.68 M	-4.68 M	-748 K	-748 K	-748 K	-748 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	39.5 M	47.1 M	51.1 M	57.4 M	65.4 M	73.3 M	78.8 M	84.1 M	88.7 M	93.5 M	99.8 M	29 M	29 M	29 M	29 M	25.2 M	25.2 M	25.2 M	25.2 M	19.6 M	19.6 M	19.6 M	19.6 M	19.5 M	19.5 M	19.5 M	19.5 M	16.4 M	16.4 M	16.4 M	16.4 M	28.1 K	28.1 K	28.1 K	28.1 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	24.6 M	32.2 M	37.3 M	43.1 M	50.4 M	58 M	66.1 M	70.9 M	75.2 M	79.5 M	86.3 M	15.2 M	15.2 M	15.2 M	15.2 M	10.7 M	10.7 M	10.7 M	10.7 M	7.13 M	7.13 M	7.13 M	7.13 M	7.71 M	7.71 M	7.71 M	7.71 M	5.01 M	5.01 M	5.01 M	5.01 M	28 K	28.1 K	28.1 K	28.1 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	35.1 M	40.3 M	45.7 M	52.2 M	58.4 M	66.4 M	72.7 M	79 M	81.3 M	84.7 M	88.5 M	17.8 M	17.8 M	17.8 M	17.8 M	15.6 M	15.6 M	15.6 M	15.6 M	14.3 M	14.3 M	14.3 M	14.3 M	17.1 M	17.1 M	17.1 M	17.1 M	15 M	15 M	15 M	15 M	-745 K	-745 K	-745 K	-745 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	35.1 M	40.3 M	45.7 M	52.2 M	58.4 M	66.4 M	72.7 M	79 M	81.3 M	84.7 M	88.5 M	17.8 M	17.8 M	17.8 M	17.8 M	15.6 M	15.6 M	15.6 M	15.6 M	14.3 M	14.3 M	14.3 M	14.3 M	17.1 M	17.1 M	17.1 M	17.1 M	15 M	15 M	15 M	15 M	-745 K	-745 K	-745 K	-745 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency